{"id":"mycobutin","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Nausea","drugRate":"65%","severity":"serious"},{"effect":"Abdominal Pain","drugRate":"43%","severity":"serious"},{"effect":"Headache","drugRate":"35%","severity":"common"},{"effect":"Diarrhea","drugRate":"33%","severity":"common"},{"effect":"Dyspepsia","drugRate":"31%","severity":"common"},{"effect":"Eructation","drugRate":"31%","severity":"common"},{"effect":"Flatulence","drugRate":"21%","severity":"mild"},{"effect":"Fever","drugRate":"21%","severity":"mild"},{"effect":"Pain","drugRate":"12%","severity":"mild"},{"effect":"Chest Pain","drugRate":"11%","severity":"mild"},{"effect":"Asthenia","drugRate":"11%","severity":"mild"},{"effect":"Vomiting","drugRate":"11%","severity":"mild"},{"effect":"Rash","drugRate":"10.8%","severity":"common"},{"effect":"Anorexia","drugRate":"22%","severity":"common"},{"effect":"Myalgia","drugRate":"21%","severity":"mild"},{"effect":"Insomnia","drugRate":"11%","severity":"mild"},{"effect":"Discolored Urine","drugRate":"30.6%","severity":"serious"},{"effect":"Increased Alkaline Phosphatase","drugRate":"13%","severity":"mild"},{"effect":"Increased SGOT","drugRate":"71.2%","severity":"serious"},{"effect":"Increased SGPT","drugRate":"91%","severity":"serious"},{"effect":"Anemia","drugRate":"67%","severity":"serious"},{"effect":"Eosinophilia","drugRate":"11%","severity":"mild"},{"effect":"Leukopenia","drugRate":"16.1%","severity":"mild"},{"effect":"Neutropenia","drugRate":"25.2%","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"5.4%","severity":"mild"},{"effect":"Uveitis","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Neutropenic disorder","Pseudomembranous enterocolitis","Thrombocytopenic disorder"]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:18:57.760851","offLabel":[],"timeline":[],"_dailymed":{"setId":"2e050d5e-3175-2c6d-e054-00144ff88e88","title":"MYCOBUTIN (RIFABUTIN) CAPSULE [DEPARTMENT OF STATE HEALTH SERVICES, PHARMACY BRANCH]"},"ecosystem":[],"mechanism":{"target":"Bacterial DNA-directed RNA polymerase, DNA-directed RNA polymerase subunit beta","modality":"Small Molecule"},"_scrapedAt":"2026-03-27T23:31:56.672Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Pulmonary Mycobacterium avium complex infection","diseaseId":"pulmonary-mycobacterium-avium-complex-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","modality→Small Molecule"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07066722","phase":"PHASE1","title":"A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2025-07-07","conditions":"HIV Infections","enrollment":126},{"nctId":"NCT07199452","phase":"PHASE1","title":"A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-28","conditions":"Healthy","enrollment":18},{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT05874544","phase":"PHASE4","title":"Rescue Therapy for Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-05-16","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07130253","phase":"NA","title":"Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-08-18","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":220},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT04616924","phase":"PHASE3","title":"RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease","status":"TERMINATED","sponsor":"RedHill Biopharma Limited","startDate":"2020-12-01","conditions":"Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases","enrollment":12},{"nctId":"NCT05684705","phase":"PHASE1","title":"Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-09-01","conditions":"Bacterial Infections","enrollment":35},{"nctId":"NCT05537142","phase":"PHASE1","title":"A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2022-09-02","conditions":"Healthy Participants","enrollment":33},{"nctId":"NCT05685615","phase":"PHASE2","title":"PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-04-20","conditions":"Ventilator Associated Pneumonia","enrollment":39},{"nctId":"NCT06731023","phase":"","title":"Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Xiuli Zuo","startDate":"2025-01-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":30},{"nctId":"NCT05458102","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-08-19","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":18},{"nctId":"NCT06687473","phase":"PHASE4","title":"Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-01-01","conditions":"Helicobacter Pylori, Drug Resistance, Multiple, Virulence Factor","enrollment":13},{"nctId":"NCT06687499","phase":"PHASE4","title":"14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2022-08-22","conditions":"Helicobacter Pylori, Drug Resistance, Multiple","enrollment":46},{"nctId":"NCT04470908","phase":"PHASE1","title":"The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males","status":"COMPLETED","sponsor":"BeiGene","startDate":"2020-07-29","conditions":"Healthy, Male","enrollment":13},{"nctId":"NCT01059422","phase":"PHASE4","title":"Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients","status":"COMPLETED","sponsor":"Central Institute of Epidemiology, Moscow, Russia","startDate":"2010-10","conditions":"HIV Infections, Tuberculosis","enrollment":10},{"nctId":"NCT04840862","phase":"PHASE4","title":"Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2022-05-09","conditions":"Drug Drug Interaction","enrollment":6},{"nctId":"NCT05537090","phase":"PHASE1","title":"A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2022-09-01","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT05684718","phase":"PHASE1","title":"To Evaluate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of BV100","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2023-02-01","conditions":"Bacterial Infections","enrollment":16},{"nctId":"NCT03891901","phase":"PHASE2","title":"A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-27","conditions":"Tuberculosis","enrollment":24},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT02256696","phase":"PHASE2","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-04-29","conditions":"Pulmonary Tuberculosis","enrollment":157},{"nctId":"NCT05086107","phase":"PHASE1","title":"Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment","status":"COMPLETED","sponsor":"BioVersys AG","startDate":"2021-10-08","conditions":"Renal Impairment","enrollment":48},{"nctId":"NCT05087069","phase":"PHASE1","title":"Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects","status":"COMPLETED","sponsor":"BioVersys SAS","startDate":"2021-10-08","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT04879992","phase":"NA","title":"Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-05-07","conditions":"Helicobacter Pylori Infection","enrollment":413},{"nctId":"NCT04672525","phase":"PHASE3","title":"Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","status":"RECRUITING","sponsor":"Tourcoing Hospital","startDate":"2021-11-08","conditions":"Prosthetic Infection","enrollment":436},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT04636983","phase":"PHASE1","title":"Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Male Subjects","status":"COMPLETED","sponsor":"BioVersys SAS","startDate":"2020-11-09","conditions":"Healthy Subjects","enrollment":54},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT00001047","phase":"PHASE3","title":"Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":400},{"nctId":"NCT00001058","phase":"PHASE2","title":"A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":246},{"nctId":"NCT00001030","phase":"PHASE3","title":"The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":1100},{"nctId":"NCT00000877","phase":"PHASE1","title":"Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":31},{"nctId":"NCT00000826","phase":"PHASE1","title":"Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Bacterial Infections, Mycoses, HIV Infections","enrollment":48},{"nctId":"NCT03618108","phase":"PHASE2","title":"Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease","status":"TERMINATED","sponsor":"Cadrock Pty. Ltd.","startDate":"2018-04-04","conditions":"Coronary Heart Disease, Chlamydophila Pneumoniae Infections","enrollment":20},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04652284","phase":"PHASE3","title":"Effectiveness of Rifabutin for Treatment of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2021-05-01","conditions":"Helicobacter Infections, Resistance Bacterial, Gastritis H Pylori","enrollment":300},{"nctId":"NCT03009396","phase":"PHASE3","title":"Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2017-03-18","conditions":"Crohn Disease","enrollment":54},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT01951326","phase":"PHASE3","title":"Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-09","conditions":"Crohn's Disease","enrollment":331},{"nctId":"NCT03149848","phase":"PHASE1","title":"Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":15},{"nctId":"NCT00513552","phase":"PHASE4","title":"Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis","status":"WITHDRAWN","sponsor":"Medstar Health Research Institute","startDate":"2007-07","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT02024555","phase":"PHASE2","title":"Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-03","conditions":"Sarcoidosis; Antimycobacterial Therapy","enrollment":97},{"nctId":"NCT03198507","phase":"PHASE3","title":"ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2017-06-18","conditions":"Helicobacter Pylori Infection, Dyspepsia","enrollment":455},{"nctId":"NCT01894776","phase":"PHASE1","title":"A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2013-06","conditions":"HIV Infection, HIV-1 Infection, Mycobacterium Avium Complex (MAC)","enrollment":15},{"nctId":"NCT02415985","phase":"PHASE2","title":"Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2015-06","conditions":"HIV, Tuberculosis","enrollment":40},{"nctId":"NCT01980095","phase":"PHASE3","title":"ERADICATE Hp - Treating Helicobacter Pylori With RHB-105","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-11","conditions":"Dyspepsia, Helicobacter Pylori Infection","enrollment":119},{"nctId":"NCT04090021","phase":"PHASE4","title":"Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.","status":"UNKNOWN","sponsor":"Konstantopoulio-Patission General Hospital of Nea Ionia","startDate":"2019-09-01","conditions":"Helicobacter Pylori Infection","enrollment":304},{"nctId":"NCT00810446","phase":"","title":"Safety And Efficacy Of Rifabutin In HIV Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Non-tuberculous Mycobacterial Diseases, Tuberculosis, Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections","enrollment":72},{"nctId":"NCT00810407","phase":"","title":"Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease)","enrollment":628},{"nctId":"NCT02968927","phase":"PHASE2","title":"TB Host Directed Therapy","status":"UNKNOWN","sponsor":"The Aurum Institute NPC","startDate":"2016-11","conditions":"Tuberculosis","enrollment":200},{"nctId":"NCT03478033","phase":"NA","title":"Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2018-04-15","conditions":"Tuberculosis, Pulmonary, AIDS","enrollment":230},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT02138084","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Rifabutin","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-05-14","conditions":"Infection, Human Immunodeficiency Virus","enrollment":102},{"nctId":"NCT01231542","phase":"PHASE1","title":"Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT00598897","phase":"PHASE4","title":"Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1995-08","conditions":"Mycobacterium Avium Complex Lung Disease","enrollment":89},{"nctId":"NCT03164291","phase":"PHASE3","title":"Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1984-06","conditions":"Nontuberculous Mycobacterial Infections","enrollment":170},{"nctId":"NCT00598962","phase":"PHASE4","title":"Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1994-12","conditions":"Mycobacterium Avium Complex","enrollment":58},{"nctId":"NCT01341184","phase":"PHASE1","title":"TMC207 +/- Rifabutin/Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-10-21","conditions":"Tuberculosis","enrollment":33},{"nctId":"NCT01717664","phase":"PHASE2","title":"Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"RedHill Biopharma Limited","startDate":"2013-06","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":18},{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864},{"nctId":"NCT02251171","phase":"PHASE1","title":"Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT02184078","phase":"PHASE4","title":"Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-10","conditions":"HIV Infections","enrollment":19},{"nctId":"NCT00869518","phase":"PHASE2","title":"Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2009-07","conditions":"Staphylococcus Aureus, HIV Infections","enrollment":12},{"nctId":"NCT00877591","phase":"PHASE1","title":"Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"Opioid Dependency, HIV Infections","enrollment":63},{"nctId":"NCT01615614","phase":"PHASE1","title":"A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2012-04","conditions":"Healthy","enrollment":20},{"nctId":"NCT00651066","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2010-06","conditions":"HIV Infections, Tuberculosis","enrollment":47},{"nctId":"NCT00646776","phase":"PHASE1","title":"Drug Interaction Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-04","conditions":"Antivirals/HIV","enrollment":85},{"nctId":"NCT01169038","phase":"PHASE1","title":"Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-07","conditions":"Pulmonary Sarcoidosis, Lung Function","enrollment":15},{"nctId":"NCT00001023","phase":"NA","title":"The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":91},{"nctId":"NCT01663168","phase":"PHASE2","title":"EARNEST Rifabutin Pharmacokinetics (PK) Substudy","status":"UNKNOWN","sponsor":"Justine Boles","startDate":"2011-12","conditions":"HIV, Tuberculosis","enrollment":140},{"nctId":"NCT00023413","phase":"PHASE2","title":"TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1999-11","conditions":"HIV Infections, Tuberculosis","enrollment":20},{"nctId":"NCT00640887","phase":"PHASE2","title":"Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-02","conditions":"HIV Infections, Tuberculosis","enrollment":48},{"nctId":"NCT01259219","phase":"PHASE1","title":"Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra","status":"UNKNOWN","sponsor":"Harriet Shezi Children's Clinic","startDate":"2010-11","conditions":"Children With Confirmed HIV Infection, Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose, Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment","enrollment":40},{"nctId":"NCT00743470","phase":"PHASE1","title":"A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects","status":"TERMINATED","sponsor":"Abbott","startDate":"2008-08","conditions":"HIV, Tuberculosis","enrollment":15},{"nctId":"NCT00925535","phase":"PHASE1","title":"Drug Interaction Study Between Rifabutin And Lersivirine (UK-453,061)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT00004736","phase":"PHASE1","title":"Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":44},{"nctId":"NCT00023348","phase":"PHASE2, PHASE3","title":"TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1999-07","conditions":"HIV Infections, Tuberculosis","enrollment":150},{"nctId":"NCT00023361","phase":"NA","title":"TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"1999-02","conditions":"HIV Infections, Tuberculosis","enrollment":215},{"nctId":"NCT00023400","phase":"PHASE4","title":"TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2000-02","conditions":"HIV Infections, Tuberculosis","enrollment":20},{"nctId":"NCT00001995","phase":"NA","title":"A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":200},{"nctId":"NCT00002343","phase":"PHASE4","title":"A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":200},{"nctId":"NCT00018083","phase":"NA","title":"Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen","status":"UNKNOWN","sponsor":"National Center for Research Resources (NCRR)","startDate":"","conditions":"Tuberculosis, HIV Infections","enrollment":""},{"nctId":"NCT00002080","phase":"NA","title":"Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":""},{"nctId":"NCT00002101","phase":"PHASE3","title":"A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":450},{"nctId":"NCT00002032","phase":"NA","title":"Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":750},{"nctId":"NCT00002267","phase":"NA","title":"Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"Pharmacia","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":750},{"nctId":"NCT00002122","phase":"PHASE3","title":"A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"","conditions":"Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections","enrollment":720}],"_emaApprovals":[],"_faersSignals":[{"count":37,"reaction":"NAUSEA"},{"count":35,"reaction":"PYREXIA"},{"count":27,"reaction":"VOMITING"},{"count":23,"reaction":"DRUG INTERACTION"},{"count":22,"reaction":"MYCOBACTERIUM AVIUM COMPLEX INFECTION"},{"count":20,"reaction":"RENAL IMPAIRMENT"},{"count":20,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":19,"reaction":"PAIN"},{"count":18,"reaction":"ASTHENIA"},{"count":18,"reaction":"HEADACHE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"Mycobutin","genericName":"Mycobutin","companyName":"Harriet Shezi Children's Clinic","companyId":"harriet-shezi-children-s-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}